<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27661058</article-id>
      <article-id pub-id-type="pmc">5044928</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000004967</article-id>
      <article-id pub-id-type="art-access-id">04967</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5800</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ocular manifestation in myeloid/NK cell precursor acute leukemia: a case report. Diagnosed by flow cytometry and PCR from aqueous humor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Akaike</surname>
            <given-names>Sayaka</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kamoi</surname>
            <given-names>Koju</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref>
            <sup>&#x2217;</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tezuka</surname>
            <given-names>Mari</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tomizawa</surname>
            <given-names>Daisuke</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>c</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshimura</surname>
            <given-names>Ryoichi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff4">
            <sup>d</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takagi</surname>
            <given-names>Masatoshi</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ohno-Matsui</surname>
            <given-names>Kyoko</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Liu.</surname>
            <given-names>Yong</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Science</aff>
      <aff id="aff2"><label>b</label>Department of Pediatrics and Developmental Biology</aff>
      <aff id="aff3"><label>c</label>Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan</aff>
      <aff id="aff4"><label>d</label>Department of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan.</aff>
      <author-notes id="cor1">
        <corresp><label>&#x2217;</label>Correspondence: Koju Kamoi, Department of Ophthalmology &amp; Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University. 1&#x2013;5&#x2013;45 Yushima, Bunkyo-ku, Tokyo 113&#x2013;8519, Japan (e-mail: <email>koju.oph@tmd.ac.jp</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <volume>95</volume>
      <issue>38</issue>
      <elocation-id>e4967</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>17</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-95-e4967.pdf"/>
      <abstract>
        <title>Abstract</title>
        <sec sec-type="background">
          <title>Background:</title>
          <p>Myeloid/NK cell precursor acute leukemia (MNKL) is a rare type of leukemia, and ocular complications have not previously been reported. We now report a patient with MNKL who developed intraocular infiltrates during follow-up.</p>
        </sec>
        <sec sec-type="methods">
          <title>Methods and Results:</title>
          <p>A 13-year-old boy diagnosed with MNKL developed left eye pain 3 months after starting treatment. Examination of the left eye revealed a visual acuity of counting fingers at 20&#x200A;cm, ciliary hyperemia, small corneal keratic precipitates, hypopyon, grade 4 vitreous opacities, and an obscured fundus. The differential diagnosis was between an opportunistic infection associated with immunodeficiency and an intraocular leukemic cell infiltrate. Therefore, a sample of aqueous humor was aspirated. Multiplex PCR/broad-range PCR of the aqueous humor was below detection limits for viruses, bacteria, and fungi. Flow cytometry (FCM) detected NK-related CD56-positive cells, thus leading to a diagnosis of ocular infiltrates due to MNKL. With treatment of the ocular infiltrates by consolidation systemic chemotherapy including intrathecal methotrexate (MTX), there was clearing of the vitreous opacities; and optic disc swelling, retinal hemorrhages, exudates, and protuberant lesions were now seen. With the addition of local radiation therapy to the eye, there was a dramatic treatment response, with regression of the optic disc findings and retinal lesions, and an improved visual acuity of 1.5.</p>
        </sec>
        <sec sec-type="conclusion">
          <title>Conclusion:</title>
          <p>We encountered the first case of MNKL in which ocular infiltrates developed during follow-up. Multiplex PCR and FCM of the aqueous humor were useful in rapidly distinguishing leukemic cell infiltrates from an opportunistic infection. This case highlights the usefulness of intrathecal MTX and local radiotherapy in treating ocular infiltrates in patients with MNKL.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>flow cytometry</kwd>
        <kwd>myeloid/NK cell precursor acute leukemia</kwd>
        <kwd>ocular infiltration</kwd>
        <kwd>ocular manifestation</kwd>
        <kwd>PCR</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <label>1</label>
      <title>Introduction</title>
      <p>Myeloid/NK cell precursor acute leukemia (MNKL) is a rare type of leukemia characterized by extramedullary lesions mainly involving the lymph nodes and mediastinum.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Usually, complete blood counts are mildly abnormal, with few leukemic cells in the peripheral blood. MNKL is a tumor at a stage similar to pluripotent stem cells originating as natural killer (NK) and myeloid cell precursors. Despite negative peroxidase staining on light microscopy, MNKL is characterized by myeloid antigen-positive, CD7-positive, and CD56-positive cells.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> No definitive treatment has been established, and because MNKL is usually refractory to chemotherapy, the prognosis is poor, with a median survival time of less than 2 years.<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#x2013;<xref rid="R3" ref-type="bibr">3</xref>]</sup></p>
      <p>We now report the first known patient with MNKL who developed an ocular lesion and in whom PCR and flow cytometry (FCM) of the aqueous humor enabled a rapid diagnosis of an ocular leukemic cell infiltrate.</p>
    </sec>
    <sec>
      <label>2</label>
      <title>Case presentation</title>
      <p>A 13-year-old boy noticed cervical lymph node swelling in October 2012 and was referred the following month to the Tokyo Medical and Dental University Hospital for further evaluation. Lymph node biopsy and bone marrow examination yielded a diagnosis of MNKL. In December 2012, he started to receive acute myeloid leukemia (AML)-oriented chemotherapy (cytarabine (Ara-C), anthracyclines, etoposide (VP-16), and triple intrathecal therapy (TIT) with methotrexate (MTX), Ara-C, and hydrocortisone (HDC)) combined with L-asparaginase (L-asp), which yielded complete remission after 2 courses of induction chemotherapies. During the first course of consolidation therapy (high-dose Ara-C, mitoxantrone (MIT), L-asp, TIT) in February 2013, the patient developed pain and decreased vision in the left eye.</p>
      <p>The initial eye examination showed a corrected visual acuity of 1.2 in the right eye and counting fingers at 20&#x200A;cm in the left eye. Intraocular pressure was normal: right eye 17&#x200A;mm Hg, left eye 13&#x200A;mm Hg. Slit lamp examination of the right eye showed no abnormalities. However, in the left eye, there were 2+ ciliary injection, 1+ corneal mutton-fat keratic precipitates, 2+ anterior chamber cells, 3+ flare, and severe hypopyon (Fig. <xref ref-type="fig" rid="F1">1</xref>A). The right eye fundus was normal, but in the left eye, the fundus was obscured because of grade 4+ vitreous opacities (Fig. <xref ref-type="fig" rid="F1">1</xref>B).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>(A) Slit lamp examination at initial evaluation. There was ciliary injection and a hypopyon in the left eye (white arrow). (B) Funduscopy at initial evaluation. The fundus was obscured due to grade 4 vitreous opacities.</p>
        </caption>
        <graphic xlink:href="medi-95-e4967-g001"/>
      </fig>
      <p>First, an opportunistic infection was considered in the differential diagnosis, so aqueous humor was aspirated, and a multiplex PCR/broad-range PCR method that we developed was performed. All results were negative, including herpes simplex virus (HSV)-1,2 (&#x2212;), varicella zoster virus (VZV) (&#x2212;), cytomegalovirus (CMV) (&#x2212;), Epstein&#x2013;Barr virus (EBV) (&#x2212;), human herpes virus (HHV)-6&#x2013;8 (&#x2212;), human T-cell leukemia virus (HTLV)-1 (&#x2212;), bacteria (&#x2212;), fungi (&#x2212;), toxoplasma (&#x2212;), and toxascaris (&#x2212;). Thus, no genes for pathogens causing opportunistic infections were detected. Next, an ocular leukemic cell infiltrate was considered in the differential diagnosis, so FCM was performed. FCM detected CD56-positive NK cells in the aqueous humor (Fig. <xref ref-type="fig" rid="F2">2</xref>). Cranial and orbital computed tomography (CT)/magnetic resonance imaging (MRI) showed no abnormalities of the orbit or the optic nerve (Fig. <xref ref-type="fig" rid="F3">3</xref>). Based on this comprehensive evaluation, ocular infiltrates associated with MNKL were diagnosed.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Flow cytometry of the aqueous humor. CD56-positive natural killer (NK) cells were detected in the aqueous humor. (A) Gating of infiltrating cells in the aqueous humor. (B) Confirmation of CD56-positive cell infiltrates (upper left panel).</p>
        </caption>
        <graphic xlink:href="medi-95-e4967-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Cranial computed tomography (CT) and magnetic resonance imaging (MRI) findings. No infiltrates of the orbit or optic nerve were present.</p>
        </caption>
        <graphic xlink:href="medi-95-e4967-g003"/>
      </fig>
      <p>Systemic chemotherapy including intrathecal MTX and anterior-oblique 2-port irradiation of the left orbit was planned. In March 2013, systemic chemotherapy with intrathecal MTX was started, the corrected visual acuity of the left eye improved to 0.6, and the vitreous opacities cleared. Examination of the fundus, which could now be visualized, showed retinal hemorrhages, exudates, protuberant lesions in the retinal periphery, and optic disc swelling (Fig. <xref ref-type="fig" rid="F4">4</xref>A). After starting radiation therapy, the protuberant lesions in the retinal periphery and the retinal exudates decreased in size.</p>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>(A) Fundus after systemic chemotherapy with intrathecal methotrexate (MTX). Corrected visual acuity was 0.6. Examination of the fundus, which could now be visualized, showed retinal hemorrhages, exudates, protuberant lesions in the retinal periphery (white arrow), and swelling of the optic disc. (B) After radiation therapy (1.5 Gy &#xD7; 17). Corrected visual acuity was 1.0. At 4 months after starting treatment, the optic disc swelling improved, the protuberant lesions in the retina disappeared, and only a few retinal exudates remained (white arrow).</p>
        </caption>
        <graphic xlink:href="medi-95-e4967-g004"/>
      </fig>
      <p>After 4 months of radiation therapy (total radiation dose: 1.5 Gy &#xD7; 17), the left eye visual acuity was 1.5, the optic disc swelling improved, the protuberant lesions in the retina disappeared, and only a few retinal exudates remained (Fig. <xref ref-type="fig" rid="F4">4</xref>B). The patient continues to be in remission for 2 years after completing the therapy.</p>
    </sec>
    <sec>
      <label>3</label>
      <title>Discussion</title>
      <p>Previously reported ocular manifestations in leukemia include direct invasion by leukemic cells, retinopathy caused by hematopoietic injury, optic neuropathy secondary to CNS leukemia, and opportunistic infections.<sup>[<xref rid="R4" ref-type="bibr">4</xref>&#x2013;<xref rid="R6" ref-type="bibr">6</xref>]</sup></p>
      <p>In this first reported case of ocular manifestations in MNKL, the aspiration of aqueous humor enabled a definitive diagnosis in a short time. Patients with leukemia are prone to developing opportunistic infections because of their decreased immune competence, so without therapy directed at pathogens, infectious endophthalmitis can progress and lead to a permanent loss of vision. Therefore, initial evaluation with multiplex PCR/broad-range PCR is useful in ruling out viral, bacterial, and fungal infections.<sup>[<xref rid="R7" ref-type="bibr">7</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>]</sup> Further testing with FCM of the aqueous humor detected NK cell&#x2013;derived CD56, a major marker expressed on leukocytes in MNKL patients. This result led to a diagnosis of ocular infiltrates. Although CD34 expression was lost in ocular-infiltrated leukemic cells, leukemic cells occasionally alter their surface antigen expression pattern based on environmental conditions or differentiation stage.</p>
      <p>Thus, PCR and FCM of the aqueous humor were able to distinguish leukemic infiltrates from an infection and were useful in helping to rapidly select appropriate treatment. This approach can be very effective in leukemic patients with ocular manifestations.</p>
      <p>Treatment of ocular leukemic cell infiltrates includes chemotherapy for the primary disease, radiation therapy, and other treatment options such as vitrectomy.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> However, treatment of ocular infiltrates due to MNKL has not been previously reported, so no definitive treatment has been established. In our patient, treatment with systemic chemotherapy including intrathecal MTX and local radiation therapy to the eye effectively resolved the infiltrates. This combination may be useful for treatment of MNKL-related ocular infiltrates.</p>
      <p>It is possible that the ocular infiltrates developed due to the treatment itself rather than MNKL. Thus, the chemotherapy may be a potential mechanism for the development of ocular infiltrates. It has been confirmed that the breakdown of the blood&#x2013;ocular barrier can be induced after treatment with systemic drugs such as cidofovir, rifabutin, bisphosphonates, interferon, and TNF&#x3B1; inhibitors.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> The drug-induced autoimmunity and toxicity mainly result in anterior segment uveitis.</p>
      <p>As for the clinical features in this case, previously reported inducible drugs were not used and infiltrates were seen not only in the anterior segment but also in the intermediate and posterior segments. Hypopyon, vitreous opacity, retinal disorders including exudates, hemorrhage, and protuberant lesions seen in this case were similar to leukemic manifestations rather than drug-induced manifestations.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R12" ref-type="bibr">12</xref>]</sup></p>
      <p>The causative relationship between ocular infiltration and MNKL could be explained by the CD56-positive infiltrating cells detected from aqueous humor by FCM. CD56 expression is associated with extramedullary leukemic infiltration.<sup>[<xref rid="R13" ref-type="bibr">13</xref>&#x2013;<xref rid="R15" ref-type="bibr">15</xref>]</sup> CD56 is a neural cell adhesion molecule isoform that plays an important role in migration through cell-to-cell adhesion via homophilic adhesion.<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup> In addition to the expression of CD56 on NK cells, CD56 is also expressed on the surface of neurons and glia.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> Therefore, it is possible that CD56 expression in leukemic cells could allow infiltration through the adhesion of leukemic cells to intraocular components that also express CD56, such as neurons, M&#xFC;ller cells, astroglia, and microglia in the retina.<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup> Thus, ocular involvement in MNKL may result from the recruiting of leukemic cells to the eye via homophilic adhesion of CD56.</p>
      <p>Taken together with PCR and FCM data, we diagnosed this patient as having ocular infiltrates due to MNKL. However, the recent findings make it difficult to perfectly describe the mechanism based on our current understanding. Further investigations need to be performed to identify the mechanism of ocular infiltration in patients with leukemia.</p>
    </sec>
    <sec>
      <label>4</label>
      <title>Conclusion</title>
      <p>To the best of our knowledge, no previous cases of ocular infiltrates in patients with MNKL have been reported. For differential diagnosis of the ocular lesion in our patient, multiplex PCR of the aqueous humor was performed to rule out an infection, and then FCM was performed, which rapidly led to a definitive diagnosis of leukemic cell infiltrates. The combination of PCR and FCM of the aqueous humor may be an important test in leukemia patients with ocular lesions. Our case study suggests that a combination of intrathecal MTX and radiation therapy is an effective treatment for ocular infiltrates in MNKL.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: Ara-C = arabinocytidine, CD = cluster of differentiation, CMV = cytomegalovirus, CT = computed tomography, EBV = Epstein&#x2013;Barr virus, FCM = flow cytometry, HDC = hydrocortisone, HHV = human herpes virus, HSV = herpes simplex virus, HTLV = human T-cell leukemia virus, L-asp = L-asparaginase, MIT = mitoxantrone hydrochloride, MNKL = myeloid/NK cell precursor acute leukemia, MRI = magnetic resonance imaging, MTX = methotrexate, NK = natural killer, VP-16 = etoposide, VZV = varicella zoster virus.</p>
      </fn>
      <fn fn-type="other">
        <p>This study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from the patient's parent for publication of this report.</p>
      </fn>
      <fn fn-type="other">
        <p>No funding was received by any of the authors in the writing of this manuscript.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors have no conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Seto</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity</article-title>. <source><italic>Blood</italic></source>
<year>1997</year>; <volume>90</volume>:<fpage>2417</fpage>&#x2013;<lpage>2428</lpage>.<pub-id pub-id-type="pmid">9310493</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>M</given-names></name><name><surname>Kondoh</surname><given-names>K</given-names></name><name><surname>Keino</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>A child with myeloid/natural killer cell precursor acute leukemia treated successfully with acute myeloid leukemia-oriented chemotherapy incorporating L-asparaginase</article-title>. <source><italic>Leuk Res</italic></source>
<year>2010</year>; <volume>34</volume>:<fpage>1677</fpage>&#x2013;<lpage>1679</lpage>.<pub-id pub-id-type="pmid">20637505</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>H</given-names></name><name><surname>Motohashi</surname><given-names>S</given-names></name><name><surname>Isozumi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside</article-title>. <source><italic>Acta Haematol</italic></source>
<year>2002</year>; <volume>108</volume>:<fpage>47</fpage>&#x2013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">12145468</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Duncan</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Ocular manifestations of leukemia: leukemic infiltration versus infectious process</article-title>. <source><italic>Ophthalmology</italic></source>
<year>2001</year>; <volume>108</volume>:<fpage>2293</fpage>&#x2013;<lpage>2300</lpage>.<pub-id pub-id-type="pmid">11733273</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>T</given-names></name><name><surname>Grewal</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role</article-title>. <source><italic>Eye (Lond)</italic></source>
<year>2004</year>; <volume>18</volume>:<fpage>663</fpage>&#x2013;<lpage>672</lpage>.<pub-id pub-id-type="pmid">15002029</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>IU</given-names></name><name><surname>Querques</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients</article-title>. <source><italic>Eur J Ophthalmol</italic></source>
<year>2008</year>; <volume>18</volume>:<fpage>619</fpage>&#x2013;<lpage>623</lpage>.<pub-id pub-id-type="pmid">18609485</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Use of multiplex PCR and real-time PCR to detect human herpes virus genome in ocular fluids of patients with uveitis</article-title>. <source><italic>Br J Ophthalmol</italic></source>
<year>2008</year>; <volume>92</volume>:<fpage>928</fpage>&#x2013;<lpage>932</lpage>.<pub-id pub-id-type="pmid">18408082</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Diagnosis of bacterial endophthalmitis by broad-range quantitative PCR</article-title>. <source><italic>Br J Ophthalmol</italic></source>
<year>2011</year>; <volume>95</volume>:<fpage>345</fpage>&#x2013;<lpage>349</lpage>.<pub-id pub-id-type="pmid">20675730</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Kamoi</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Detection of Candida and Aspergillus species DNA using broad-range real-time PCR for fungal endophthalmitis</article-title>. <source><italic>Graefes Arch Clin Exp Ophthalmol</italic></source>
<year>2012</year>; <volume>250</volume>:<fpage>391</fpage>&#x2013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">21947326</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Use of a comprehensive polymerase chain reaction system for diagnosis of ocular infectious diseases</article-title>. <source><italic>Ophthalmology</italic></source>
<year>2013</year>; <volume>120</volume>:<fpage>1761</fpage>&#x2013;<lpage>1768</lpage>.<pub-id pub-id-type="pmid">23664179</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Doycheva</surname><given-names>D</given-names></name><name><surname>Zierhut</surname><given-names>M</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Zierhut</surname><given-names>M</given-names></name><name><surname>Pavesio</surname><given-names>C</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Orefice</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group>
<article-title>Drug-induced uveitis</article-title>. <source><italic>Intraocular Inflammation</italic></source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer-Verlag Berlin Heidelberg</publisher-name>; <year>2016</year>; <comment>Chapter 155</comment>.</mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zierhut</surname><given-names>M</given-names></name><name><surname>Haen</surname><given-names>SP</given-names></name><name><surname>Moehle</surname><given-names>R</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Zierhut</surname><given-names>M</given-names></name><name><surname>Pavesio</surname><given-names>C</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Orefice</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><etal/></person-group>
<article-title>Hematological neoplasms</article-title>. <source><italic>Intraocular Inflammation</italic></source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer-Verlag Berlin Heidelberg</publisher-name>; <year>2016</year>; <comment>Chapter 149</comment>.</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iizuka</surname><given-names>Y</given-names></name><name><surname>Aiso</surname><given-names>M</given-names></name><name><surname>Oshimi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Myeloblastoma formation in acute myeloid leukemia</article-title>. <source><italic>Leuk Res</italic></source>
<year>1992</year>; <volume>16</volume>:<fpage>665</fpage>&#x2013;<lpage>671</lpage>.<pub-id pub-id-type="pmid">1378918</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Brandwein</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>QL</given-names></name><etal/></person-group>
<article-title>Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome</article-title>. <source><italic>Leuk Res</italic></source>
<year>2004</year>; <volume>28</volume>:<fpage>1007</fpage>&#x2013;<lpage>1011</lpage>.<pub-id pub-id-type="pmid">15289011</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiftik</surname><given-names>N</given-names></name><name><surname>Bolaman</surname><given-names>Z</given-names></name><name><surname>Batun</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>The importance of CD7 and CD56 antigens in acute leukaemias</article-title>. <source><italic>Int J Clin Pract</italic></source>
<year>2004</year>; <volume>58</volume>:<fpage>149</fpage>&#x2013;<lpage>152</lpage>.<pub-id pub-id-type="pmid">15055863</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Estrov</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia</article-title>. <source><italic>Leuk Res</italic></source>
<year>2002</year>; <volume>26</volume>:<fpage>643</fpage>&#x2013;<lpage>649</lpage>.<pub-id pub-id-type="pmid">12008081</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zocchi</surname><given-names>MR</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Poggi</surname><given-names>A</given-names></name></person-group>
<article-title>Involvement of CD56/N-CAM molecule in the adhesion of human solid tumor cell lines to endothelial cells</article-title>. <source><italic>Exp Cell Res</italic></source>
<year>1993</year>; <volume>204</volume>:<fpage>130</fpage>&#x2013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">7677984</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garin-Chesa</surname><given-names>P</given-names></name><name><surname>Fellinger</surname><given-names>EJ</given-names></name><name><surname>Huvos</surname><given-names>AG</given-names></name><etal/></person-group>
<article-title>Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence</article-title>. <source><italic>Am J Pathol</italic></source>
<year>1991</year>; <volume>139</volume>:<fpage>275</fpage>&#x2013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">1867319</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
